Published in Sci Rep on January 13, 2016
Driving gene-engineered T cell immunotherapy of cancer. Cell Res (2016) 0.89
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
Structural mechanism underpinning cross-reactivity of a CD8+ T-cell clone that recognises a peptide derived from human telomerase reverse transcriptase. J Biol Chem (2016) 0.79
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
XDS. Acta Crystallogr D Biol Crystallogr (2010) 67.46
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol (2006) 7.57
Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature (1996) 6.20
A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today (1998) 5.07
T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol (2004) 3.85
Deconstructing the peptide-MHC specificity of T cell recognition. Cell (2014) 3.24
How a single T cell receptor recognizes both self and foreign MHC. Cell (2007) 3.20
Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol (2005) 2.97
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng (2003) 2.75
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
Decision making in xia2. Acta Crystallogr D Biol Crystallogr (2013) 2.59
Crystal structure of a T cell receptor bound to an allogeneic MHC molecule. Nat Immunol (2000) 2.37
Analyzing a kinetic titration series using affinity biosensors. Anal Biochem (2005) 2.27
TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol (2002) 2.12
CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nat Immunol (2003) 2.10
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem (2011) 2.06
Human TCR-binding affinity is governed by MHC class restriction. J Immunol (2007) 2.02
Why must T cells be cross-reactive? Nat Rev Immunol (2012) 1.88
T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity (2011) 1.86
Microorganisms and autoimmunity: making the barren field fertile? Nat Rev Microbiol (2003) 1.76
T cell antigen receptor recognition of antigen-presenting molecules. Annu Rev Immunol (2014) 1.64
Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) 1.57
Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides. Eur J Immunol (2014) 1.49
Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol (2010) 1.48
Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol (2012) 1.46
"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer (2010) 1.43
Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol (2012) 1.41
Selection of functional T cell receptor mutants from a yeast surface-display library. Proc Natl Acad Sci U S A (1999) 1.38
Rfree and the rfree ratio. II. Calculation Of the expected values and variances of cross-validation statistics in macromolecular least-squares refinement. Acta Crystallogr D Biol Crystallogr (2000) 1.37
Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci (2006) 1.31
Structural and biophysical determinants of αβ T-cell antigen recognition. Immunology (2012) 1.30
Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. Protein Eng Des Sel (2007) 1.19
Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLoS Pathog (2010) 1.18
T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Mol Immunol (2008) 1.18
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012) 1.16
Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol (2003) 1.05
T-cell receptor specificity maintained by altered thermodynamics. J Biol Chem (2013) 0.94
T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. J Biol Chem (2013) 0.93
Computational design and crystal structure of an enhanced affinity mutant human CD8 alphaalpha coreceptor. Proteins (2007) 0.93
Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Sci Rep (2012) 0.90
TCR/pMHC Optimized Protein crystallization Screen. J Immunol Methods (2012) 0.89
Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode. Front Immunol (2013) 0.88
Crossreactivity of a human autoimmune TCR is dominated by a single TCR loop. Nat Commun (2013) 0.83